MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Schrodinger Inc

Cerrado

SectorSanidad

18.64 1.47

Resumen

Variación precio

24h

Actual

Mínimo

18.11

Máximo

18.69

Métricas clave

By Trading Economics

Ingresos

10M

-33M

Ventas

-435K

54M

Margen de beneficios

-60.369

Empleados

891

EBITDA

10M

-31M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+17.3% upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-150M

1.4B

Apertura anterior

17.17

Cierre anterior

18.64

Noticias sobre sentimiento de mercado

By Acuity

7%

93%

4 / 370 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Schrodinger Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ene 2026, 23:54 UTC

Charlas de Mercado

CBA Could Underperform Again in 2026 -- Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

12 ene 2026, 23:43 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ene 2026, 23:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ene 2026, 21:56 UTC

Charlas de Mercado

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

12 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 21:18 UTC

Charlas de Mercado

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ene 2026, 20:54 UTC

Ganancias

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ene 2026, 20:48 UTC

Charlas de Mercado

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ene 2026, 20:33 UTC

Charlas de Mercado

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ene 2026, 20:18 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ene 2026, 19:39 UTC

Charlas de Mercado

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ene 2026, 19:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 ene 2026, 19:33 UTC

Charlas de Mercado

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ene 2026, 19:24 UTC

Adquisiciones, fusiones, absorciones

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ene 2026, 19:22 UTC

Adquisiciones, fusiones, absorciones

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ene 2026, 18:21 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ene 2026, 18:20 UTC

Adquisiciones, fusiones, absorciones

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ene 2026, 18:19 UTC

Charlas de Mercado

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ene 2026, 18:16 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

12 ene 2026, 18:09 UTC

Charlas de Mercado

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ene 2026, 18:01 UTC

Adquisiciones, fusiones, absorciones

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ene 2026, 18:00 UTC

Charlas de Mercado

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparación entre iguales

Cambio de precio

Schrodinger Inc previsión

Precio Objetivo

By TipRanks

17.3% repunte

Estimación a 12 Meses

Media 21.83 USD  17.3%

Máximo 25 USD

Mínimo 18 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Schrodinger Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

4

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.13Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Very Strong Bullish Evidence

Sentimiento

By Acuity

4 / 370 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat